Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates

被引:45
|
作者
Hirt, Deborah [1 ,2 ]
Urien, Saik [1 ,2 ]
Rey, Elisabeth [3 ]
Arrive, Elise [4 ]
Ekouevi, Didier K. [5 ]
Coffie, Patrick [5 ]
Leang, Sim Kruy [6 ]
Lalsab, Sarita [7 ]
Avit, Divine [5 ]
Nerrienet, Eric [8 ]
McIntyre, James [7 ]
Blanche, Stephane [9 ]
Dabis, Francois [4 ]
Treluyer, Jean-Marc [1 ,2 ,3 ]
机构
[1] Univ Paris 05, EA3620, Paris, France
[2] Hop Tarnier, AP HP, Unite Rech Clin, F-75006 Paris, France
[3] Univ Paris 05, Hop Cochin St Vincent de Paul, AP HP, Serv Pharmacol Clin, Paris, France
[4] Univ Victor Segalen, INSERM, ISPED, U897, Bordeaux, France
[5] ANRS Abidjan, Programme PAC CI, Abidjan, Cote Ivoire
[6] Hop Calmette, Serv Gynecol Obstet, Phnom Penh, Cambodia
[7] Univ Witwatersrand, Chris Hani Baragwanath Hosp, Perinatal HIV Res Unit PHRU, Johannesburg, South Africa
[8] Inst Pasteur Cambodge, Phnom Penh, Cambodia
[9] Univ Paris 05, Hop Necker Enfants Malad, Serv Immunol & Hematol Pediat, Paris, France
关键词
DISOPROXIL FUMARATE; RESISTANCE; NEVIRAPINE; TENOFOVIR; QUANTIFICATION; PHARMACOLOGY;
D O I
10.1128/AAC.00860-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets-two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h(-1) (61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters.h(-1), and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg.liter(-1).h and 1.68 and 0.076 mg/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg.liter(-1). We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.
引用
收藏
页码:1067 / 1073
页数:7
相关论文
共 50 条
  • [41] STREPTOCOCCUS-PNEUMONIAE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED CHILDREN
    GESNER, M
    DESIDERIO, D
    KIM, M
    KAUL, A
    LAWRENCE, R
    CHANDWANI, S
    POLLACK, H
    RIGAUD, M
    KRASINSKI, K
    BORKOWSKY, W
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (08) : 697 - 703
  • [42] Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects
    Veronese, FD
    Arnott, D
    Barnaba, V
    Loftus, DJ
    Sakaguchi, K
    Thompson, CB
    Salemi, S
    Mastroianni, C
    Sette, A
    Shabanowitz, J
    Hunt, DF
    Appella, E
    JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06): : 2509 - 2516
  • [43] The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons
    Veldkamp, AI
    Harris, M
    Montaner, JSG
    Moyle, G
    Gazzard, B
    Youle, M
    Johnson, M
    Kwakkelstein, MO
    Carlier, H
    van Leeuwen, R
    Beijnen, JH
    Lange, JMA
    Reiss, P
    Hoetelmans, RMW
    JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (01): : 37 - 42
  • [44] Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers
    Thomas, DL
    Villano, SA
    Riester, KA
    Hershow, R
    Mofenson, LM
    Landesman, SH
    Hollinger, FB
    Davenny, K
    Riley, L
    Diaz, C
    Tang, HB
    Quinn, TC
    JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (06): : 1480 - 1488
  • [45] Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine
    Janoff, EN
    Fasching, C
    Ojoo, JC
    OBrien, J
    Gilks, CF
    JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (04): : 975 - 978
  • [46] Virus-specific cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected chimpanzees
    Santra, S
    Fultz, PN
    Letvin, NL
    JOURNAL OF VIROLOGY, 1999, 73 (08) : 7065 - 7069
  • [47] Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients
    Dubois, V
    Dutronc, H
    Lafon, ME
    Poinsot, V
    Pellegrin, JL
    Ragnaud, JM
    Ferrer, AM
    Fleury, HJA
    JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (09) : 2288 - 2292
  • [48] Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus
    Csajka, C
    Marzolini, C
    Fattinger, K
    Décosterd, LA
    Telenti, A
    Biollaz, M
    Buclin, T
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) : 3226 - 3232
  • [49] IMMUNOSUPPRESSION IN PREGNANT-WOMEN INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS
    BIGGAR, RJ
    PAHWA, S
    MINKOFF, H
    MENDES, H
    WILLOUGHBY, A
    LANDESMAN, S
    GOEDERT, JJ
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1989, 161 (05) : 1239 - 1244
  • [50] Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995-1999
    Sitnitskaya, Y
    Rochford, G
    Rigaud, M
    Essajee, S
    Pollack, H
    Krasinski, K
    Borkowsky, W
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (01) : E3 - E7